Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JERRY BAGEL

Allopathic & Osteopathic Physicians Dermatology

NPI
1992772156
CMS profile
226194
Location
EAST WINDSOR, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$241,037.80

278 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 6; records 101–150 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JERRY BAGEL

NPI 1992772156 · CMS profile ID 226194

Allopathic & Osteopathic Physicians / Dermatology

EAST WINDSOR, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992772156?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JERRY BAGEL, NPI 1992772156, CMS profile ID 226194. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992772156?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JERRY BAGEL, NPI 1992772156, CMS profile ID 226194. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992772156?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JERRY BAGEL, NPI 1992772156, CMS profile ID 226194, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 278 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1992772156?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

278 matching records · $241,037.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 278 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 278.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $13.1809/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807402235 CMS
Janssen Biotech, Inc. $14.6609/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788901555 CMS
Lilly USA, LLC $168.0009/02/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818566465 CMS
Lilly USA, LLC $24.0009/02/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819150159 CMS
UCB, Inc. $10,620.0008/30/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807472109 CMS
Galderma Laboratories, L.P. $11.6308/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855262397 CMS
Lilly USA, LLC $1,750.0008/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818557381 CMS
Lilly USA, LLC $2,800.0008/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818567513 CMS
Janssen Biotech, Inc. $13.4608/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788901589 CMS
Lilly USA, LLC $1,400.0008/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818566463 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $14.6008/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851891607 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $44.8008/25/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851891619 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $115.6208/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851891625 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $4,400.0008/25/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851891627 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,480.0008/24/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763774346 CMS
Lilly USA, LLC $61.0208/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819122786 CMS
Novartis Pharmaceuticals Corporation $14.7008/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812596763 CMS
Novartis Pharmaceuticals Corporation $1,200.0008/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812596807 CMS
UCB, Inc. $14.0908/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807388537 CMS
AbbVie Inc. $14.3408/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793957001 CMS
Lilly USA, LLC $1,400.0008/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819173331 CMS
UCB, Inc. $81.2208/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807412961 CMS
Regeneron Healthcare Solutions, Inc. $14.1208/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809557093 CMS
AbbVie Inc. $4,900.0008/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793956989 CMS
AbbVie Inc. $13.0608/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793956993 CMS
AbbVie Inc. $1.3908/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793956997 CMS
Novartis Pharmaceuticals Corporation $13.0108/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812596811 CMS
AbbVie Inc. $25.7808/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793956985 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $83.6508/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763774344 CMS
Janssen Biotech, Inc. $93.3308/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788901571 CMS
UCB, Inc. $122.9808/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807451255 CMS
Lilly USA, LLC $14.8308/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818577235 CMS
Novartis Pharmaceuticals Corporation $13.9108/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812596761 CMS
Galderma Laboratories, L.P. $14.1008/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855262395 CMS
Novartis Pharmaceuticals Corporation $1,200.0008/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812596805 CMS
UCB, Inc. $3.0908/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807373621 CMS
Janssen Biotech, Inc. $12.7507/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788901539 CMS
LEO Pharma Inc. $52.4907/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842137775 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $14.6307/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851891609 CMS
EPI Health, LLC $15.0607/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854622737 CMS
Mindera Corp $2,275.0007/27/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855500929 CMS
Novartis Pharmaceuticals Corporation $12.3407/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812596817 CMS
Allergan, Inc. $11.3007/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792696919 CMS
Janssen Biotech, Inc. $13.8907/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788901575 CMS
Regeneron Healthcare Solutions, Inc. $2,112.0007/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809557091 CMS
AbbVie Inc. $14.9507/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793956981 CMS
UCB, Inc. $14.5707/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807370575 CMS
Janssen Scientific Affairs, LLC $1,013.0007/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788901619 CMS
Lilly USA, LLC $2,800.0007/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818567511 CMS
Lilly USA, LLC $1,750.0007/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818577231 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $260,988.73 345
PY2020 $121,506.75 167
PY2021 $241,037.80 278
PY2022 $319,785.75 392
PY2023 $225,636.12 341
PY2024 $173,204.06 316
PY2025 $218,714.00 283

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $797,065.37 260
PY2024 Recipient $26,977.86 2
PY2024 Principal investigator $1,895,847.54 706
PY2023 Recipient $392,196.81 12
PY2023 Principal investigator $1,391,205.66 410
PY2022 Recipient $11,071.33 11
PY2022 Principal investigator $1,496,091.59 247
PY2021 Recipient $58,182.05 19
PY2021 Principal investigator $2,017,632.60 255
PY2020 Recipient $163,342.55 13
PY2020 Principal investigator $1,360,186.40 226
PY2019 Recipient $290,883.58 21
PY2019 Principal investigator $4,913,153.54 200

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

260 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,086.83 12/12/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289698
Principal investigator 1 Incyte Corporation $6,209.10 12/08/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619135
Principal investigator 1 Incyte Corporation $52.14 12/01/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619066
Principal investigator 1 Incyte Corporation $21.33 12/01/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619078
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619107
Principal investigator 1 Incyte Corporation $18.96 12/01/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619119
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619126
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619144
Principal investigator 1 Incyte Corporation $14.22 12/01/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619148
Principal investigator 1 Incyte Corporation $14.22 12/01/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619153
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $19,109.07 12/01/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289007
Principal investigator 1 Incyte Corporation $2,531.00 11/24/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619073
Principal investigator 1 Incyte Corporation $1,050.10 11/24/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619111
Principal investigator 1 Incyte Corporation $1,629.00 11/24/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619114
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 11/20/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184263791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 11/20/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184263793
Principal investigator 1 Incyte Corporation $1,158.30 11/12/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619069
Principal investigator 1 Incyte Corporation $2,169.00 11/12/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619122
Principal investigator 1 Incyte Corporation $4.24 11/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619081
Principal investigator 1 Incyte Corporation $49.36 11/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619085
Principal investigator 1 Incyte Corporation $16.44 11/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619089
Principal investigator 1 Incyte Corporation $16.44 11/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619093
Principal investigator 1 Incyte Corporation $16.44 11/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619096
Principal investigator 1 Incyte Corporation $16.44 11/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619100
Principal investigator 1 Incyte Corporation $270.80 11/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 10/23/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184253194
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,000.00 10/22/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY DBA ECZEMA TREATMENT CENTER OF CENTRAL NEW JERSEY
PILOT STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF DUPILUMAB IN COMBINATION WITH NARROWBAND UVB (NUVB) PHOTOTHERAPY IN THE TREATMENT OF MODERATE-TO-SEVERE AD No dispute reported 06/30/2026 1184251568
Principal investigator 1 Incyte Corporation $959.90 10/20/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619129
Principal investigator 1 Incyte Corporation $2,531.00 10/20/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619163
Principal investigator 1 Incyte Corporation $2,531.00 10/20/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619167
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $22,077.61 10/15/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286993
Principal investigator 1 ABBVIE INC. $4,000.00 10/09/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202516371
Principal investigator 1 ABBVIE INC. $2,932.10 10/09/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202516373
Principal investigator 1 Incyte Corporation $1,187.80 10/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619139
Principal investigator 1 Incyte Corporation $2,531.00 10/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619177
Principal investigator 1 Incyte Corporation $3.18 10/01/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619103
Principal investigator 1 Incyte Corporation $48.54 10/01/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619159
Principal investigator 1 Incyte Corporation $68.70 10/01/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619172
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 09/25/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184243011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 09/25/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184243013
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $27,413.35 09/23/2025 Non-covered Recipient Entity
Schweiger Dermatology And Allergy East Windsor
A Single Center Study to Evaluate the Effectiveness and Safety of Deucravacitinib in combination with Enstilar for Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1235993761
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,512.09 09/23/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285836
Principal investigator 1 Incyte Corporation $7,500.00 09/22/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619027
Principal investigator 1 Incyte Corporation $2,500.00 09/22/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619052
Principal investigator 1 Incyte Corporation $1,350.00 09/10/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 09/04/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184235107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 09/04/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184235109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 09/04/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184235111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 09/04/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184235113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 09/04/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184235115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 09/04/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184235117
Principal investigator 1 ABBVIE INC. $702.30 09/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202507887
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.00 08/27/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284635
Principal investigator 1 Janssen Research & Development, LLC $4,787.00 08/25/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175433065
Principal investigator 1 Incyte Corporation $1,821.40 08/20/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619012
Principal investigator 1 Incyte Corporation $1,482.00 08/20/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619019
Principal investigator 1 Incyte Corporation $1,601.00 08/20/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619056
Principal investigator 1 Incyte Corporation $1,482.00 08/20/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619059
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,818.29 08/19/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284371
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,338.26 08/13/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284221
Principal investigator 1 ABBVIE INC. $2,357.50 08/06/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202502863
Principal investigator 1 ABBVIE INC. $2,106.90 08/05/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202501586
Principal investigator 1 Incyte Corporation $270.80 08/04/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619045
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 08/04/2025 Non-covered Recipient Entity
Schweiger Derm and Allergy-East Windsor
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175244351
Principal investigator 1 Janssen Research & Development, LLC $1,683.00 08/04/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175433001
Principal investigator 1 Incyte Corporation $1,350.00 08/01/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619024
Principal investigator 1 Janssen Research & Development, LLC $2,462.00 08/01/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175432971
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,368.79 08/01/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283607
Principal investigator 1 ABBVIE INC. $22,877.50 07/31/2025 Non-covered Recipient Entity
PSORIASIS TREATMENT CENTER OF CENTRAL NEW JERSEY
A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Relative Bioavailability of Risankizumab Following Subcutaneous Administration with On-Body Injector No dispute reported 06/30/2026 1202500588
Principal investigator 1 Janssen Research & Development, LLC $4,947.00 07/28/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175433026
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 07/24/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184218491
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,928.16 07/24/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283082
Principal investigator 1 Incyte Corporation $865.40 07/18/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619031
Principal investigator 1 Incyte Corporation $1,601.00 07/18/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619036
Principal investigator 1 Incyte Corporation $1,482.00 07/18/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619049
Principal investigator 1 Incyte Corporation $1,601.00 07/18/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619064
Principal investigator 1 Janssen Research & Development, LLC $1,427.00 07/10/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175433054
Principal investigator 1 Incyte Corporation $1,952.10 07/09/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619040
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,505.23 07/09/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223282432
Principal investigator 1 ABBVIE INC. $2,932.10 07/02/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202494231
Principal investigator 1 ABBVIE INC. $5,350.28 07/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202494233
Principal investigator 1 Janssen Research & Development, LLC $2,462.00 06/27/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175432981
Principal investigator 1 Janssen Research & Development, LLC $1,616.00 06/26/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175433071
Principal investigator 1 Incyte Corporation $1,482.00 06/25/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618881
Principal investigator 1 Incyte Corporation $1,966.50 06/25/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618885
Principal investigator 1 Incyte Corporation $417.00 06/25/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 06/19/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184209420
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 06/19/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184209422
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 06/19/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184209424
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 06/19/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184209426
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 06/19/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184209428
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 06/19/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184209430
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 06/19/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184209432
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 06/19/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184209434
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 06/19/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184209438
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 06/19/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184209440
Principal investigator 1 Incyte Corporation $1,222.00 06/11/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618867
Principal investigator 1 Incyte Corporation $1,280.00 06/11/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618901
Principal investigator 1 Janssen Research & Development, LLC $1,427.00 06/09/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175433049
Principal investigator 1 ABBVIE INC. $2,323.99 06/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202487535
Principal investigator 1 ABBVIE INC. $1,530.40 06/03/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202487537
Principal investigator 1 Incyte Corporation $32.36 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524250
Principal investigator 1 Incyte Corporation $34.35 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524255
Principal investigator 1 Incyte Corporation $9.72 06/03/2025 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240524260
Principal investigator 1 Incyte Corporation $16.44 06/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618918
Principal investigator 1 Incyte Corporation $12.36 06/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618929
Principal investigator 1 Incyte Corporation $27.81 06/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618941
Principal investigator 1 Incyte Corporation $148.85 06/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618950
Principal investigator 1 Incyte Corporation $6.36 06/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618955
Principal investigator 1 Incyte Corporation $64.72 06/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618959
Principal investigator 1 Incyte Corporation $16.44 06/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618974
Principal investigator 1 Incyte Corporation $16.44 06/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618978
Principal investigator 1 Incyte Corporation $16.44 06/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618981
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,910.00 06/02/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280576
Principal investigator 1 Janssen Research & Development, LLC $11,000.00 05/30/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175433032
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $22,077.61 05/27/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280338
Principal investigator 1 Janssen Research & Development, LLC $6,388.00 05/26/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175433059
Principal investigator 1 Janssen Research & Development, LLC $10,676.00 05/22/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175432995
Principal investigator 1 Janssen Research & Development, LLC $1,616.00 05/22/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175433036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 05/22/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184198415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 05/22/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184198419
Principal investigator 1 Incyte Corporation $1,482.00 05/21/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618847
Principal investigator 1 Incyte Corporation $1,143.90 05/21/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618870
Principal investigator 1 Incyte Corporation $417.00 05/21/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618874
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,373.83 05/16/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279918
Principal investigator 1 ABBVIE INC. $5,567.37 05/07/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202482419
Principal investigator 1 ABBVIE INC. $2,611.00 05/07/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202482421
Principal investigator 1 Eli Lilly and Company $14,993.00 05/07/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187889056
Principal investigator 1 Incyte Corporation $1,350.00 05/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618878
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618897
Principal investigator 1 Incyte Corporation $24.66 05/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618904
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618912
Principal investigator 1 Incyte Corporation $8.48 05/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618963
Principal investigator 1 Incyte Corporation $1,333.80 05/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618966
Principal investigator 1 Incyte Corporation $406.20 05/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618970
Principal investigator 1 Incyte Corporation $7.29 05/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618985
Principal investigator 1 Incyte Corporation $24.66 05/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618990
Principal investigator 1 Incyte Corporation $24.66 05/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618994
Principal investigator 1 Incyte Corporation $24.66 05/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618996
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619001
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619004
Principal investigator 1 Janssen Research & Development, LLC $3,797.00 04/28/2025 Non-covered Recipient Entity
Schweiger Derm and Allergy-East Windsor
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175244406
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $24,951.70 04/17/2025 Non-covered Recipient Entity
Schweiger Dermatology And Allergy East Windsor
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) No dispute reported 06/30/2026 1235993759
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $25,700.00 04/11/2025 Non-covered Recipient Entity
Schweiger Dermatology And Allergy East Windsor
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis No dispute reported 06/30/2026 1235993757
Principal investigator 1 Eli Lilly and Company $3,096.00 04/10/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187889054
Principal investigator 1 Incyte Corporation $1,656.00 04/09/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618859
Principal investigator 1 Incyte Corporation $1,034.40 04/09/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618863
Principal investigator 1 Incyte Corporation $1,500.00 04/09/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240619008
Principal investigator 1 ABBVIE INC. $9,265.06 04/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202469982
Principal investigator 1 ABBVIE INC. $10,455.75 04/03/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202469986
Principal investigator 1 Incyte Corporation $2,396.00 04/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618843
Principal investigator 1 Incyte Corporation $2,396.00 04/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618851
Principal investigator 1 Incyte Corporation $961.70 04/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618855
Principal investigator 1 Incyte Corporation $42.23 04/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618894
Principal investigator 1 Incyte Corporation $74.04 04/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618909
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618921
Principal investigator 1 Incyte Corporation $16.18 04/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618925
Principal investigator 1 Incyte Corporation $74.04 04/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618933
Principal investigator 1 Incyte Corporation $0.93 04/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618938
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618945
Principal investigator 1 Janssen Research & Development, LLC $1,995.00 03/31/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175433014
Principal investigator 1 Janssen Research & Development, LLC $2,462.00 03/27/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175432978
Principal investigator 1 Janssen Research & Development, LLC $8,263.00 03/24/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175433007
Principal investigator 1 Eli Lilly and Company $12,194.00 03/18/2025 Non-covered Recipient Entity
JERRY BAGEL MD LLC
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1187885224
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,431.00 03/14/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276735
Principal investigator 1 Incyte Corporation $1,500.00 03/12/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618590
Principal investigator 1 Incyte Corporation $1,200.00 03/12/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618594
Principal investigator 1 ABBVIE INC. $7,251.71 03/07/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202459774
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,719.59 03/07/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276141
Principal investigator 1 Janssen Research & Development, LLC $1,995.00 03/06/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175432987
Principal investigator 1 ABBVIE INC. $2,418.60 03/04/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202455586
Principal investigator 1 Incyte Corporation $49.36 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618711
Principal investigator 1 Incyte Corporation $1,333.80 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618730
Principal investigator 1 Incyte Corporation $10.60 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618733
Principal investigator 1 Incyte Corporation $68.70 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618740
Principal investigator 1 Incyte Corporation $64.72 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618744
Principal investigator 1 Incyte Corporation $0.62 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618749
Principal investigator 1 Incyte Corporation $41.10 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618754
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618758
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618761
Principal investigator 1 Incyte Corporation $14.58 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618766
Principal investigator 1 Incyte Corporation $74.04 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618769
Principal investigator 1 Incyte Corporation $41.10 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618773
Principal investigator 1 Incyte Corporation $32.36 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618792
Principal investigator 1 Incyte Corporation $41.10 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618801
Principal investigator 1 Incyte Corporation $41.10 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618804
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618811
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618816
Principal investigator 1 Incyte Corporation $148.85 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618823
Principal investigator 1 Janssen Research & Development, LLC $3,797.00 03/03/2025 Non-covered Recipient Entity
Windsor Derm
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175244389
Principal investigator 1 Janssen Research & Development, LLC $1,875.00 03/03/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175433078
Principal investigator 1 Janssen Research & Development, LLC $2,462.00 03/03/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175433084
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $19,851.66 03/03/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275877
Principal investigator 1 UCB SA $880.00 02/27/2025 Non-covered Recipient Entity
THE PSORIASIS TREATMENT CENTER OF CENTRAL NEW JERSEY
A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa No dispute reported 06/30/2026 1246657582
Principal investigator 1 Eli Lilly and Company $2,495.04 02/25/2025 Non-covered Recipient Entity
EMKEY ARTHRITIS AND OSTEOPOROSIS
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187880585
Principal investigator 1 Janssen Research & Development, LLC $45.00 02/25/2025 Non-covered Recipient Entity
Schweiger Derm Group-East Windsor
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175244375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 02/20/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155086
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 02/20/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155090
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 02/20/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155092
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,402.83 02/14/2025 Non-covered Recipient Entity
Schweiger Dermatology And Allergy East Windsor
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235993763
Principal investigator 1 ABBVIE INC. $3,023.10 02/11/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy No dispute reported 06/30/2026 1202450504
Principal investigator 1 Incyte Corporation $1,443.60 02/10/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618623
Principal investigator 1 Janssen Research & Development, LLC $6,317.00 02/07/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175433042
Principal investigator 1 ABBVIE INC. $4,442.51 02/06/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202449720
Principal investigator 1 Biofrontera Inc. $67,250.00 01/31/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC PSORIASIS TREATMENT CENTER OF CENTRAL NEW JERSEY
A SINGLE CENTER, OBSERVATIONAL STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF CRYOTHERAPY IN COMBINATION WITH AMELUZ RED LIGHT PDT IN THE TREATMENT OF ACTINIC KERATOSES ON THE FULL FACE. No dispute reported 06/30/2026 1208907279
Principal investigator 1 Janssen Research & Development, LLC $2,400.00 01/31/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175433020
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,680.49 01/31/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY DBA ECZEMA TREATMENT CENTER OF CENTRAL NEW JERSEY
PILOT STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF DUPILUMAB IN COMBINATION WITH NARROWBAND UVB (NUVB) PHOTOTHERAPY IN THE TREATMENT OF MODERATE-TO-SEVERE AD No dispute reported 06/30/2026 1184151258
Principal investigator 1 Incyte Corporation $1,482.00 01/27/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618631
Principal investigator 1 Incyte Corporation $1,482.00 01/27/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618635
Principal investigator 1 Incyte Corporation $1,144.50 01/27/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618808
Principal investigator 1 Janssen Research & Development, LLC $20,368.95 01/23/2025 Non-covered Recipient Entity
Schweiger Derm Group-East Windsor
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175244343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 01/23/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184149458
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 01/23/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184149460
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 01/23/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184149462
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 01/23/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184149466
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 01/23/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184149468
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,429.90 01/22/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274407
Principal investigator 1 Eli Lilly and Company $61,422.00 01/21/2025 Non-covered Recipient Entity
JERRY BAGEL MD LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187885570
Principal investigator 1 Janssen Research & Development, LLC $7,914.00 01/16/2025 Non-covered Recipient Entity
Windsor Derm
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175244360
Principal investigator 1 Incyte Corporation $1,399.20 01/15/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618599
Principal investigator 1 Incyte Corporation $2,389.00 01/15/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618601
Principal investigator 1 Incyte Corporation $1,500.00 01/15/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618606
Principal investigator 1 Incyte Corporation $1,500.00 01/15/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618611
Principal investigator 1 Incyte Corporation $417.00 01/15/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618615
Principal investigator 1 Incyte Corporation $1,644.00 01/15/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618619
Principal investigator 1 ABBVIE INC. $3,037.50 01/02/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202436061
Principal investigator 1 Incyte Corporation $259.70 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618627
Principal investigator 1 Incyte Corporation $275.60 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618639
Principal investigator 1 Incyte Corporation $233.20 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618643
Principal investigator 1 Incyte Corporation $80.70 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618647
Principal investigator 1 Incyte Corporation $222.60 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618651
Principal investigator 1 Incyte Corporation $116.60 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618655
Principal investigator 1 Incyte Corporation $100.70 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618659
Principal investigator 1 Incyte Corporation $68.90 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618663
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618667
Principal investigator 1 Incyte Corporation $43.04 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618669
Principal investigator 1 Incyte Corporation $43.04 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618672
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618674
Principal investigator 1 Incyte Corporation $32.28 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618677
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618681
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618687
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618690
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618694
Principal investigator 1 Incyte Corporation $37.10 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618697
Principal investigator 1 Incyte Corporation $14.58 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618702
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618706
Principal investigator 1 Incyte Corporation $54.76 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618714
Principal investigator 1 Incyte Corporation $0.93 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618717
Principal investigator 1 Incyte Corporation $74.04 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618723
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618726
Principal investigator 1 Incyte Corporation $16.18 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618736
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618777
Principal investigator 1 Incyte Corporation $63.60 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618781
Principal investigator 1 Incyte Corporation $22.90 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618784
Principal investigator 1 Incyte Corporation $406.20 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618787
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618797
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618826
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618832
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618837
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240618840